Most cited papers from Helsinn (Switzerland)

Helsinn (Switzerland)

What are the most cited papers from Helsinn (Switzerland)?

The most cited paper from Helsinn (Switzerland) is "NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016" (David S. Ettinger et al., 2016), with 739 citations. Next come "Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron" (473) and "Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist" (405).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 24 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network Open access	Mar 2016	739
2	Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Richard J. Gralla, M. Lichinitser, Stefan van der Vegt et al. · Annals of Oncology Open access	19 Sep 2003	473
3	Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · Cancer Open access	17 Nov 2003	405
4	A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Matti Aapro, Steven M. Grunberg, George M. Manikhas et al. · Annals of Oncology Open access	10 Jun 2006	342
5	Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor Camilo J. Rojas, Marigo J. Stathis, Ajit Thomas et al. · Anesthesia & Analgesia	Aug 2008	254
6	A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy Matti Aapro, H. S. Rugo, Antônio Rossi et al. · Annals of Oncology Open access	7 Mar 2014	251
7	Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study Paul Joseph Hesketh, Antônio Rossi, Giada Rizzi et al. · Annals of Oncology Open access	9 Mar 2014	228
8	Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function Camilo J. Rojas, Ajit G. Thomas, Jesse Alt et al. · European Journal of Pharmacology	16 Oct 2009	202
9	A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy Richard J. Gralla, Snezana M. Bosnjak, A. Hontsa et al. · Annals of Oncology Open access	15 Mar 2014	194
10	Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects Randall R. Stoltz, Jong‐Chol Cyong, Ajit K. Shah et al. · The Journal of Clinical Pharmacology	21 Apr 2004	159
11	A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo in Preventing Postoperative Nausea and Vomiting Over a 72-Hour Period Anthony L. Kovac, Leopold Eberhart, Jan Kotarski et al. · Anesthesia & Analgesia	Aug 2008	157
12	Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study Peter D. Eisenberg, F. Roy MacKintosh, Paul S. Ritch et al. · Annals of Oncology Open access	Feb 2004	154
13	Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy Matti Aapro, Alessandra Fabi, Franco Nolè et al. · Annals of Oncology Open access	16 Jan 2010	149
14	A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo for Preventing Postoperative Nausea and Vomiting Keith A. Candiotti, Anthony L. Kovac, Timothy I. Melson et al. · Anesthesia & Analgesia	Aug 2008	139
15	The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo Camilo J. Rojas, Ying Li, Jie Zhang et al. · Journal of Pharmacology and Experimental Therapeutics Open access	20 Aug 2010	134
16	A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) Lillian F. Zhang, Shun Lü, J. Feng et al. · Annals of Oncology Open access	27 Oct 2017	116
17	Anamorelin HCl (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile Claudio Pietra, Yasuhiro Takeda, Naoko Tazawa-Ogata et al. · Journal of Cachexia Sarcopenia and Muscle Open access	29 Sep 2014	114
18	Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities A. B. Bennett, Giuliana Villa · Expert Opinion on Pharmacotherapy	2000	102
19	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study Guillermo Garcia‐Manero, Yasmin Abaza, Koichi Takahashi et al. · Blood Advances Open access	13 Feb 2019	89
20	Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects Marigo J. Stathis, Claudio Pietra, Camilo J. Rojas et al. · European Journal of Pharmacology	7 Jun 2012	87
21	A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin Paolo Bossi, Diego Luigi Cortinovis, Sonia Fatigoni et al. · Annals of Oncology Open access	26 Jun 2017	86
22	Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) Lee Steven Schwartzberg, Sally Yowell Barbour, Gary R. Morrow et al. · Supportive Care in Cancer Open access	18 Oct 2013	77
23	Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance Marco Sardella et al. · Therapeutic Advances in Drug Safety Open access	2021	66
24	In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant Anna Rizzi, Barbara Campi, Valeria Camarda et al. · Peptides	22 Jun 2012	62
25	Netupitant PET imaging and ADME studies in humans Tulla Spinelli, Selma Calcagnile, Claudio Giuliano et al. · The Journal of Clinical Pharmacology Open access	12 Oct 2013	59
26	New ghrelin agonist, HM 01 alleviates constipation and L‐dopa‐delayed gastric emptying in 6‐hydroxydopamine rat model of P arkinson's disease Hiroshi Karasawa, Claudio Pietra, Claudio Giuliano et al. · Neurogastroenterology & Motility Open access	19 Oct 2014	58
27	Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model Robert S. Northrup, Ken Kuroda, Elizabeth Manning Duus et al. · Supportive Care in Cancer Open access	11 Apr 2013	51
28	Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity‐related metabolic disease Kathrin Abegg, Lara Bernasconi, Melanie Hutter et al. · Diabetes Obesity and Metabolism Open access	25 May 2017	50
29	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron Matti Aapro, Meinolf Karthaus, Lee Steven Schwartzberg et al. · Supportive Care in Cancer Open access	24 Nov 2016	48
30	Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study Gábor Géza Kovács, Antonio E. Wachtel, Е В Башарова et al. · The Lancet Oncology	18 Jan 2016	48
31	Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey Matti Aapro, Pierfrancesco Ruffo, Roger Panteri et al. · Cancer Reports Open access	9 Oct 2018	47
32	Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteers Randall R. Stoltz, Simona Parisi, Ajit K. Shah et al. · Biopharmaceutics & Drug Disposition	20 Sep 2004	42
33	Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy Lee Schwartzberg, Eric J. Roeland, Zoran Gojko Andric et al. · Annals of Oncology Open access	May 2018	41
34	Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone Corinna Lanzarotti, Giorgia Rossi · Supportive Care in Cancer	31 May 2013	41
35	Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations Isao Miyazaki et al. · Nature Cancer Open access	21 Sep 2023	40
36	Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial Ralph Vincent Boccia, Steven M. Grunberg, Edwin Franco-Gonzales et al. · Supportive Care in Cancer Open access	25 Jan 2013	40
37	Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors Fabienne Olivia Villars, Claudio Pietra, Claudio Giuliano et al. · International Journal of Molecular Sciences Open access	5 May 2017	37
38	The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats Bronwen J. Mayo, Kate R. Secombe, Anthony D. Wignall et al. · Cancer Chemotherapy and Pharmacology	14 Feb 2020	36
39	Nimesulide in the Treatment of Osteoarthritis R.-L. Dreiser, D. Riebenfeld · Drugs	1993	36
40	IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance Zoë Johnson, Chiara Tarantelli, Elisa Civanelli et al. · Cancer Research Communications Open access	16 Mar 2023	34
41	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy Lee Steven Schwartzberg, Rudolph M. Navari, Rebecca Anne Clark-Snow et al. · The Oncologist Open access	4 Dec 2019	34
42	The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats Tito Borner, Laura Loi, Claudio Pietra et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology	5 May 2016	32
43	Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. M. G. Pochobradsky, Giuseppina Mele, Abril Beretta et al. · PubMed	1991	31
44	DOUBLE‐BLIND STUDY COMPARING THE LONG‐TERM EFFICACY OF THE COX‐2 INHIBITOR NIMESULIDE AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS Walter Kriegel, KJ Korff, JC Ehrlich et al. · International Journal of Clinical Practice Open access	Oct 2001	31
45	Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis Armando Porto, Conceição Reis, Rui Perdigoto et al. · Current Therapeutic Research Open access	Sep 1998	31
46	Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial Tulla Spinelli, Cecilia Moresino, Sybille Baumann et al. · SpringerPlus Open access	29 Jul 2014	31
47	Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives Selma Calcagnile, Corinna Lanzarotti, Giorgia Rossi et al. · Supportive Care in Cancer	9 Jun 2013	31
48	Implementing Historical Controls in Oncology Trials Olivier Collignon, Anna Schritz, Riccardo Spezia et al. · The Oncologist Open access	2 Feb 2021	30
49	Nimesulide Binding to Components within Blood Françoise Brée, P Nguyen, Saı̈k Urien et al. · Drugs	1993	28
50	What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy Eric J. Roeland, Kathryn J. Ruddy, Thomas William LeBlanc et al. · Journal of the National Comprehensive Cancer Network Open access	Jun 2020	27

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.